A registration trial of CPI-444 in late-stage renal cancer patients.

Trial Profile

A registration trial of CPI-444 in late-stage renal cancer patients.

Planning
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs CPI 444 (Primary)
  • Indications Renal cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Nov 2017 According to a Corvus Pharmaceuticals media release, this trial is expected to begin in 2018.
    • 13 Jan 2017 New trial record
    • 10 Jan 2017 According to a Corvus Pharmaceuticals media release, based on the positive data from Phase 1/1b trial (see profile 262434) company is planning to initiate this trial before the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top